Kineta, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KA research report →
Price Chart
About the company
Kineta, Inc. is a clinical-stage biotechnology firm dedicated to developing immunotherapies, with a focus on oncology, neuroscience, and biodefense applications. The company engages in partnerships with a variety of entities, including private companies, government bodies, and other industry stakeholders.
- CEO
- Craig W. Philips
- IPO
- 2016
- Employees
- 11
- HQ
- Seattle, WA, US
Get TickerSpark's AI analysis on KA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $7.05M
- P/E
- -0.40
- PEG
- -0.01
- P/S
- 0.00
- P/B
- -0.58
- EV/EBITDA
- -0.52
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 374.84%
- ROIC
- 120.41%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $0-100.0%
- Op Income
- $-13,532,000
- Net Income
- $-17,132,000-21.5%
- EPS
- $-1.42-10.9%
- OCF Growth
- +28.6%
- FCF Growth
- +28.6%
- 52W High
- $5.39
- 52W Low
- $0.33
- 50D MA
- $0.65
- 200D MA
- $1.12
- Beta
- 0.57
- RSI (14)
- 48
- Avg Volume
- 504.10K
No earnings-call transcripts are available for KA yet.
- Free Float
- 65.1%
- Shares Outstanding
- 12.26M
- Float Shares
- 7.98M
of shares held by institutions
25 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock Inc. | 5.54K | ▼ 13.51K |
Held by 10 ETFs
Biggest fund positions in KA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 4, 24 | Peters Richard | other | 12,500 |
| Sep 4, 24 | Iadonato Shawn | other | 12,500 |
| Sep 4, 24 | Foote Marion R | other | 12,500 |
| Sep 4, 24 | Dylla Scott J. | other | 12,500 |
| Sep 4, 24 | Drapkin Kimberlee C | other | 12,500 |
| Sep 4, 24 | Bartoszek Raymond J. | other | 12,500 |
| Sep 4, 24 | Arkowitz David | other | 12,500 |
| May 1, 24 | Bartoszek Raymond J. | other | 903,995 |
| Apr 14, 24 | Iadonato Shawn | other | 225,000 |
| Apr 14, 24 | PHILIPS CRAIG W. | other | 225,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our KA coverage
Recent articles, reports, and earnings notes.
No research on KA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate KA report →TuHURA Biosciences Completes Acquisition of Kineta
prnewswire.com · Jun 30
TuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals
prnewswire.com · Jun 23
TuHURA Biosciences and Kineta Present Updated Results from Kineta's Phase I-II Study of KVA12123 and TuHURA's Mechanism of IFx-Hu2.0 Responses After Anti-PD-1 Therapy Failure in Advanced Melanoma at the American Association for Cancer Research Annual Meeting
prnewswire.com · Apr 28
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of TuHURA Biosciences, Inc. - HURA
prnewswire.com · Dec 12
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Kineta, Inc. - KANT
prnewswire.com · Dec 12
TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc.
accesswire.com · Dec 12
Kineta Updates KVA12123 Clinical Results from Ongoing Phase 1/2 VISTA101 Study at Society for Immunotherapy of Cancer (2024)
globenewswire.com · Nov 8
Kineta Announces KVA12123 Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024
globenewswire.com · Oct 4
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.